Emergent Biosolutions, Inc. (EBS) is a publicly traded Healthcare sector company. As of September 21, 2026, EBS trades at $6.83 with a market cap of $348.66M and a P/E ratio of -2.01. EBS moved -3.13% today. Year to date, EBS is -44.98%; over the trailing twelve months it is -14.36%. Its 52-week range spans $4.02 to $14.06. Analyst consensus is neutral with an average price target of $10.00. Rallies surfaces EBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks EBS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $6.83 |
| Market Cap | $348.66M |
| P/E Ratio | -2.01 |
| EPS | $-3.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.06 |
| 52-Week Low | $4.02 |
| Volume | 892.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $770.20M |
| Net Income | $-176.80M |
| Gross Margin | 55.87% |
2 analysts cover EBS: 0 strong buy, 1 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $10.00.